NeuroPace (NPCE) Short term Debt (2020 - 2021)
NeuroPace (NPCE) posted Short term Debt of $3.6 million for Q1 2021, up 75.72% on a QoQ basis from $2.0 million in Q4 2020.
Powered by 
Analysis
NeuroPace (NPCE) Short term Debt (2020 - 2021) Analysis & Trends
NeuroPace has reported Short term Debt for 2 years, with the latest figure at $3.6 million in Q1 2021.
- On a quarterly basis, Short term Debt changed N/A year-over-year to $3.6 million in Q1 2021; TTM through Mar 2021 was $3.6 million, a N/A change from a year earlier, with the FY2020 full-year figure at $2.0 million, changed N/A from the prior year.
- Short term Debt was $3.6 million for Q1 2021 at NeuroPace, up from $2.0 million in the prior quarter.
- The five-year high for Short term Debt was $3.6 million in Q1 2021, with the low at $2.0 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | NeuroPace | 493.15 Mn | 441.45 Mn | 18.91 Mn |